Gene Logic Inc. Establishes Agreement with Merck Serono to Discover New Development Paths for Multiple Clinical-Stage Drug Candidates
GAITHERSBURG, Md.--(BUSINESS WIRE)--Gene Logic Inc. (NASDAQ:GLGC) announced today that it has entered into a drug repositioning and development agreement with Merck Serono, a division of Merck KGaA of Germany, to seek alternative development paths for several Merck Serono drug candidates. All of these drug candidates were discontinued or de-prioritized in clinical trials for reasons other than safety.